Insud Pharma
Enrique Gallego Lucena is currently the Head of Data + Global Platforms & Digital Applications at Insud Pharma, where responsibilities include defining and implementing IT strategy, leading teams, and managing strategic projects related to Data Analytics and SAP systems. With over 20 years of experience at Accenture, Enrique held various managerial positions, including Senior Manager and Implementation Director, focusing on technology consulting, project and program management, and digital transformation for top-tier clients across multiple industries. An alumnus of prestigious institutions including IE Business School and Kellogg Executive Education, Enrique holds degrees in Law and Business Administration, complemented by specialized training in data strategy and leadership development.
This person is not in any teams
This person is not in any offices
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.